NC6's Principal Activity is the research and development, and promotion of the Companyï¿½??s microbial cellulose technology. The primary focus has been directed towards the development, scale up and ultimate commercialisation of the Companyï¿½??s Plant-Free rayon fibre for use in textiles (nullarborTM) and non-woven applications (nufoliumï¿½??).
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-4.68%|
|vs ASX 200 (1yr)||-8.39%|
Nanollose Limited (NC6) is an Australian based biotechnology company that deals in the research and development, and promotion of the Company's microbial cellulose technology. The primary focus has been directed towards the development of the Company's Plant-Free viscose-rayon fibre (Nullarbor). The Company also continued its activities towards developing a commercial supply chain of microbial cellulose from a variety of waste streams.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|Ms Heidi Beatty||Non-Executive Director||Jul 2019||
Ms Heidi Beatty
Ms Beatty, founder of Crown Abbey Ltd is a scientist and innovator who has 20 years' experience developing consumer and health care products. She worked with Johnson & Johnson for 10 years in Europe and the US. In 2015 she founded Crown Abbey Ltd, a consultancy company that supports clients in their project launches, combining Project Management and Product Development across Consumer and Healthcare categories.
|Mr Terence (Terry) Walsh||Non-Executive Director||Aug 2016||
Mr Terence (Terry) Walsh
Mr Walsh is a senior commercial lawyer and manager with more than 20 years of experience in project development, mining and general commercial law. He initially worked with leading law firms in Perth and Sydney before moving in house, where he has worked as the General Counsel of Hancock Prospecting Pty Ltd and prior to that as a Corporate Counsel with Rio Tinto Ltd. In these roles he has been involved with the legal and commercial aspects associated with the development and operation of technology and mining projects.
|Dr Wayne Morris Best||Executive Chairman,Executive Director||Sep 2014||
Dr Wayne Morris Best
Executive Chairman,Executive Director
Dr Best has 40 years' experience in organic chemistry both in academia, government and industry. He then spent two years at Imperial College in the UK where he obtained a DIC, followed by a year at the Australian National University in Canberra. He then took up a position with ICI Australia's Research Group in Melbourne for four and a half years which included a secondment to ICI Agrochemicals in the UK. Following ICI, he returned to Western Australia and spent ten years at the Chemistry Centre (WA) where he was responsible for the formation and running of the Medicinal & Biological Chemistry Section which undertook collaborative R&D into drug discovery and contract synthesis for the drug discovery and pharmaceutical industries. He then founded Epichem Pty Ltd, a contract research and drug discovery Company, which he managed for 14 years before moving full-time to Nanollose in 2018 He has served as a Director for several listed and unlisted biotechnology companies. He was a former director of Pharmaust Limited.
|Mr Winton William Willesee||Non-Executive Director||Sep 2014||
Mr Winton William Willesee
Mr Willesee is an experienced company director and secretary with over 20 years' experience in various roles within the Australian capital markets. Mr Willesee has considerable experience with ASX listed and other companies over a broad range of industries having been involved with many successful ventures from early stage through to large capital development projects. He has a core expertise in strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance
|Ms Erlyn Dale||Company Secretary||N/A|
NC6 directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|17/05/22||Terence (Terry) Walsh||Buy||+197,168||$0.09||$17,665||On-market trade|
|31/12/21||Wayne Best||Expiry||2,000,000||$0.10||$200,000||As advised by the company|
|07/12/21||Winton Willesee||Buy||+500,000||$0.105||$52,500||As advised by the company|
|07/12/21||Terence (Terry) Walsh||Buy||+500,000||$0.105||$52,500||As advised by the company|
|14/01/21||Winton Willesee||Buy||+170,000||$0.083||$14,110||On-market trade|
|04/12/20||Raffaele (Alfie) Germano||Issued||2,000,000||$0.049||$98,000||Director remuneration|
|04/12/20||Raffaele (Alfie) Germano||Issued||146,796||$0.026||$3,750||Director remuneration|
|04/12/20||Raffaele (Alfie) Germano||Issued||500,000||$0.049||$24,500||Conversion of securities|
|04/12/20||Raffaele (Alfie) Germano||Exercise||500,000||$0.049||$24,500||Conversion of securities|
|04/12/20||Terence (Terry) Walsh||Issued||68,504||$0.026||$1,750||Director remuneration|
|04/12/20||Winton Willesee||Issued||68,504||$0.026||$1,750||Director remuneration|
|04/12/20||Heidi Beatty||Issued||500,000||$0.049||$24,500||Director remuneration|
|04/12/20||Heidi Beatty||Issued||68,504||$0.026||$1,750||Director remuneration|
|04/12/20||Wayne Best||Issued||2,000,000||$0.049||$98,000||Director remuneration|
|04/12/20||Wayne Best||Issued||146,796||$0.026||$3,750||Director remuneration|
|13/05/20||Winton Willesee||Issued||2,237,143||$0.024||$53,691||Rights issue|
|13/05/20||Wayne Best||Issued||2,367,144||$0.024||$56,811||Rights issue|
|13/05/20||Terence (Terry) Walsh||Issued||200,000||$0.024||$4,800||Rights issue|
|13/05/20||Raffaele (Alfie) Germano||Issued||200,000||$0.024||$4,800||Rights issue|
|20/11/19||Wayne Best||Issued||2,000,000||$0.071||$142,000||Issue of securities|
|20/11/19||Raffaele (Alfie) Germano||Issued||2,000,000||$0.071||$142,000||Issue of securities|
The current holdings of NC6 directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Terence (Terry) Walsh||17/05/2022||700,000||265,672||500,000||N/A|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Azalea Family Holdings Pty Ltd||19/08/2021||8,068,504||5.43|
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|24-06-21||Azalea Family Holdings Pty Ltd||2,550,647||7.36||5.43|
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.